These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39620475)

  • 1. The impact of
    Chouaid C; Giannopoulou A; Starry A; Stollenwerk B; Bozorgmehr F
    J Med Econ; 2025 Dec; 28(1):13-24. PubMed ID: 39620475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
    Zhou Q; Meng X; Sun L; Huang D; Yang N; Yu Y; Zhao M; Zhuang W; Guo R; Hu Y; Pan Y; Shan J; Sun M; Yuan Y; Fan Y; Huang J; Liu L; Chu Q; Wang X; Xu C; Lin J; Huang J; Huang M; Sun J; Zhang S; Zhou H; Wu YL
    J Thorac Oncol; 2024 Dec; 19(12):1630-1639. PubMed ID: 39127176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life Evaluation in Patients with Follicular Cell Lymphoma: A Real-World Study in Europe and the United States.
    Johnson PC; Bailey A; Ma Q; Milloy N; Biondi E; Quek RGW; Weatherby S; Barlow S
    Adv Ther; 2024 Aug; 41(8):3342-3361. PubMed ID: 38976122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EORTC QLU-C10D distinguished better between cancer patients and the general population than PROPr and EQ-5D-5L in a cross-sectional study.
    Döhmen A; Obbarius A; Kock M; Nolte S; Sidey-Gibbons CJ; Valderas JM; Rohde J; Rieger K; Fischer F; Keilholz U; Rose M; Klapproth CP
    J Clin Epidemiol; 2024 Nov; 177():111592. PubMed ID: 39515489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
    Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
    Kishnani PS; Byrne BJ; Claeys KG; Díaz-Manera J; Dimachkie MM; Kushlaf H; Mozaffar T; Roberts M; Schoser B; Hummel N; Kopiec A; Holdbrook F; Shohet S; Toscano A;
    J Patient Rep Outcomes; 2024 Nov; 8(1):132. PubMed ID: 39535661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
    Swaminath A; Parpia S; Wierzbicki M; Kundapur V; Faria S; Okawara GS; Tsakiridis TK; Ahmed N; Bujold A; Hirmiz K; Owen T; Leong N; Ramchandar K; Filion E; Lau H; Gabos Z; Thompson R; Yaremko B; Mehiri S; Louie AV; Quan K; Levine MN; Wright JR; Whelan TJ
    JAMA Oncol; 2024 Nov; 10(11):1571-1575. PubMed ID: 39298144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic impact of first-line or drug-naïve catheter ablation and delayed second-line catheter ablation for atrial fibrillation using a patient-level simulation model.
    Arbelo E; De Ponti R; Cohen L; Pastor L; Costa G; Hempel M; Grima D
    J Med Econ; 2024; 27(1):1168-1179. PubMed ID: 39254662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.
    Cabart M; Mourey L; Pasquier D; Schneider S; Léna H; Girard N; Chouaid C; Schott R; Hiret S; Debieuvre D; Quantin X; Madroszyk A; Dubray-Longeras P; Pichon E; Baranzelli A; Justeau G; Pérol M; Bosquet L; Cabarrou B
    J Geriatr Oncol; 2024 Sep; 15(7):101819. PubMed ID: 39068144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EQ-5D-5L population norms and health inequality for Trinidad and Tobago in 2022-2023 and comparison with 2012.
    Bailey H; Jonker MF; Pullenayegum E; Rencz F; Roudijk B
    Health Qual Life Outcomes; 2024 Nov; 22(1):103. PubMed ID: 39609861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Frailty and Its Impact on Quality of Life in Older Patients With Breast Cancer: A Prospective Cross-Sectional Study.
    Xiao M; Chen X; Ji L; Qian X; Xiu M; Li Z; Cao H; Chen S; Li Q; Li Q; Wang X; Wang J; Li Y; Zheng X; Zhang P
    J Clin Nurs; 2024 Dec; ():. PubMed ID: 39654080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and its associated factors among Chinese seasonal retired migrants in Hainan.
    Chen S; Li T; Wang L; Wang S; Ouyang L; Wang J; Hu D; Yu J
    PeerJ; 2024; 12():e18574. PubMed ID: 39583106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
    Hibino M; Imamura Y; Shimoyama R; Fukui T; Fukai R; Iwase A; Tamura Y; Chihara Y; Okabe T; Uryu K; Okuda T; Taguri M; Minami H
    Target Oncol; 2024 Nov; 19(6):925-939. PubMed ID: 39302602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.